Single-center study links PSMA PET staging to longer survival in localized prostate cancer

Retrospective · J Nucl Med · 2026-10-30. Number 1 in the UrologyWatch Top 5 for October 31, 2026.

In a retrospective cohort of 6,999 men with localized prostate cancer, the 7.2% who underwent PSMA PET/CT for primary staging had longer time to biochemical recurrence and longer cancer-specific and overall survival after adjustment and propensity matching, with benefit concentrated in high-risk patients treated with radiotherapy.

Why it matters: Hypothesis generating: selection bias for who received PSMA PET at a single center may not be fully resolved by matching, so this should not be read as proof that PET itself improves survival.

Limitation: Single-center retrospective design with only 7.2% of the cohort receiving PSMA PET, raising strong selection bias concerns despite propensity adjustment.

Source: J Nucl Med · PubMed 42957210 · DOI 10.2967/jnumed.126.273261

The full October 31, 2026 edition · Today's urology news